Company: PFSA
Filing Date: 2025-04-28
Form Type: S-4/A
Source: 0001213900-25-035718
Chunk: 36

Company: Profusa, Inc.
Filing Date: 2025-04-28
Form: S-4/A
Chunk 36
---
22, 2025, or amend the NorthView Amended and Restated Certificate of Incorporation to further extend the date by which NorthView must consummate an initial business combination, NorthView’s Amended and Restated Certificate of Incorporation provides that NorthView will: (i) cease all operations except for the purpose of winding up; (ii) redeem the public shares of NorthView Common Stock at a per -shareprice equal to the aggregate amount then on deposit in the Trust Account, including interest (net of taxes payable), divided by the number of then outstanding public shares of NorthView Common Stock, which redemption will completely extinguish NorthView Holders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii) as promptly as reasonably possible following such redemption, subject to the approval of NorthView’s remaining stockholders and NorthView’s Board, dissolve and liquidate, subject in each case to NorthView’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. See the section entitled “ Risk Factors — Risks Related to NorthView and the Business Combination.” The NorthView Initial Stockholders have waived any right to any liquidation distribution with respect to their shares of NorthView Common Stock. In the event of liquidation, there will be no distribution with respect to outstanding NorthView Warrants or NorthView Rights. Accordingly, the NorthView Warrants and the NorthView Rights will expire worthless. Q:What equity stake will current NorthView stockholders and current Profusa shareholders hold in the combined company immediately after consummation of the Business Combination? A:As of the date of this proxy statement/prospectus, there are 5,348,311shares of NorthView Common Stock outstanding, which includes an aggregate of 4,743,750shares of NorthView Common Stock held by the Sponsor. In addition, as of the date of this proxy statement/prospectus, there is outstanding an aggregate of 17,404,250 warrants to acquire NorthView Common Stock, comprised of 7,347,500 private placement warrants held by the Sponsor and Representatives, 9,487,500 public warrants, and 569,250 Representative Warrants. Each whole warrant will entitle the holder thereof to purchase one share of NorthView Common Stock at an exercise price of $11.50 per share. Additionally, there are 1,897,500shares issuable pursuant to the 18,975,000 NorthView